Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Universal Ibogaine Inc ( (TSE:IBO) ) is now available.
Universal Ibogaine Inc. held its annual meeting of shareholders, where nine board members were elected, and MNP LLP was re-appointed as the company’s auditors. However, the company’s 2025 Employee Equity Incentives Plan and 2024 Stock Option Plan were not re-approved due to insufficient shareholder approval. The company announced the grant of 13,500,000 Restricted Share Units to its CEO and consultants, with vesting scheduled for one year after the grant date. These developments may impact the company’s operational strategies and its approach to employee incentives.
More about Universal Ibogaine Inc
Universal Ibogaine Inc. is a life sciences company focused on transforming addiction treatment through medicalized ibogaine. The company aims to conduct a Canadian clinical trial for opioid use disorder and expand its treatment protocol globally through future licensing agreements. Additionally, UI is developing a holistic addiction treatment protocol at its Kelburn Recovery Centre in Manitoba, which is intended to revolutionize addiction treatment.
Average Trading Volume: 312,818
Technical Sentiment Signal: Sell
Current Market Cap: C$5.5M
For a thorough assessment of IBO stock, go to TipRanks’ Stock Analysis page.